9 unknown. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Unknown 9 |
| Phase 2 | 5 | Unknown 5 |
Follow palbociclib: new trials by email Literature Review of palbociclib trials Research Report on palbociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) ZB716, Palbociclib - Estrogen Receptor-Positive, HER2-Negative | Phase 1 / Phase 2 | Unknown | EnhancedBio USA Inc. | 106 | 2021-07-26 | 2022-03-22 |
| Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer CYH33, Fulvestrant, Letrozole - Advanced Breast Cancer | Phase 1 | Unknown | Haihe Biopharma Co., Ltd. | 228 | 2021-04-01 | 2021-04-23 |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE Binimetinib, Encorafenib, Palbociclib - Melanoma, Metastasis | Phase 1 / Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 78 | 2020-06-04 | 2024-01-05 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms Palbociclib, Rivaroxaban, SNP - Cancer, Solid Tumor | Phase 1 | Unknown | Lebanese University | 500 | 2019-02-01 | 2023-10-06 |
| Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma Palbociclib, Cetuximab, Intensity Modulated Radiation Therapy - Head and Neck Cancer, Locally Advanced | Phase 1 / Phase 2 | Unknown | Mahidol University | 27 | 2017-07-19 | 2024-03-15 |
| Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer Gedatolisib, Faslodex, Palbociclib - Breast Cancer | Phase 1 | Unknown | Hoffman Oncology | 18 | 2016-01-01 | 2022-02-09 |
| Study of Palbociclib in MLL-rearranged Acute Leukemias Palbociclib - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | University of Ulm | 50 | 2015-07-01 | 2019-04-16 |
| Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma PD- 0332991 - Melanoma BRAF V600E/K Mutated, CDNKN2A Loss Defined | Phase 1 / Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 40 | 2014-05-01 | 2016-04-18 |
| PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies PD-0332991, 5-FU, Oxaliplatin - Advanced Solid Tumor Malignancies | Phase 1 | Unknown | Georgetown University | 37 | 2011-12-01 | 2020-03-04 |
Breast Neoplasms (3) · Melanoma (2) · Neoplasms (2) · Carcinoma, Hepatocellular (1) · Cardiovascular Diseases (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Immune System Diseases (1) · Inflammation (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms (1) · Thromboembolism (1)
Assistance Publique - Hôpitaux de Paris (1) · EnhancedBio USA Inc. (1) · Georgetown University (1) · Haihe Biopharma Co., Ltd. (1) · Hoffman Oncology (1) · Lebanese University (1) · Mahidol University (1) · Peter MacCallum Cancer Centre, Australia (1) · University of Ulm (1)
United States (3) · Australia (1) · France (1) · Germany (1) · Lebanon (1) · South Korea (1) · Thailand (1)
Anthony Hoffman, MD (1) · Grant McArthur, Prof (1) · Michael Pishvaian, MD PhD (1) · Nehman Makdissy, Professor (1) · Nuttapong Ngamphaiboon, MD (1)